April 1, 2024
Our Specialty Medical Injectables with Reimbursement Restriction guidelines state that certain injectables must be dispensed and their claims must be submitted by a Cigna Healthcare–contracted specialty pharmacy, unless otherwise authorized by Cigna Healthcare.
The reimbursement restriction:
Specialty Medical Injectables with Reimbursement Restriction list expansion
We recently expanded the Specialty Medical Injectables with Reimbursement Restriction list to include the specialty medical injectables listed below.*
Name | Effective date |
Anktiva® | August 5, 2024 |
Piasky® | July 29, 2024 |
Rytelo® | July 15, 2024 |
Padcev® (enfortumab vedotin-ejfv) | October 1, 2024** |
Trodelvy® (sacituzumab govitecan-hziy) | October 1, 2024** |
Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) | October 1, 2024 |
Lunsumio® (mosunetuzumab-axgb) | January 1, 2024 |
Additional information
To access the Specialty Medical Injectables with Reimbursement Restriction list, log in to the Cigna for Health Care Professionals website (CignaforHCP.com) > Resources > Reimbursement and Payment Policies > Precertification Policies > List of Specialty Medical Injectables with Reimbursement Restriction. We recommend you review this list frequently, as it is subject to change. Specialty medical injectables may be added upon U.S. Food and Drug Administration approval.
*Cigna Healthcare may grant an exception to reimburse a one-time, or single, administration billed by a facility when a customer needs access to the injectable before it can be obtained from a specialty pharmacy with which Cigna Healthcare has a reimbursement arrangement.
**Effective January 1, 2025, for Individual & Family Plans.
Please let us know what you think of the Provider Newsroom information and news.
Contact Us